List view / Grid view
According to a report, the desire to reduce waste, technological advancement and regulatory standards will all drive the adoption of biodegradable pharmaceutical packaging.
Pfizer and BioNTech have agreed to supply the European Union with 200 million additional doses of COMIRNATY in 2021, making the total 500 million doses.
YuflymaTM (CT-P17) has been approved for the treatment of thirteen chronic inflammatory diseases, including rheumatoid arthritis, ulcerative colitis and psoriatic arthritis, in Europe.
The approval makes Ogluo™ Europe’s first ready-to-use liquid glucagon for rescuing diabetic patients from severe hypoglycaemic events.
After manufacturing delays, AstraZeneca will now provide the EU with the 40 million COVID-19 vaccine doses it originally agreed to supply.
The company announced that the Phase I/II trial for VLA2001 is now fully enrolled and that it has begun manufacturing the vaccine candidate on an industrial scale.
AbbVie's RINVOQ (upadacitinib) has been approved in the EU to treat adult patients with active psoriatic arthritis (PsA).
EPR's Victoria Rees interviews Dr Jaime Oliver Vigueras from Janssen to discuss rilpivirine, Janssen's long acting monthly injectable HIV treatment.
The Europe Commission is currently in discussions to procure millions of doses of Valneva’s COVID-19 innactivated virus vaccine, VLA2001.
Richard Daniell explains why Europe needs a strong pharmaceutical manufacturing base and supply chain to ensure a resilient network.
The EMA has received a conditional marketing authorisation application for the Oxford-AstraZeneca COVID-19 vaccine.
Moderna's COVID-19 vaccine has been approved in the EU with a conditional marketing authorisation by the European Commission.
Aimmune Therapeutics' PALFORZIA® has been approved by the European Commission as a treatment for peanut allergy.
The European Commission approval of the long-acting injectable HIV treatment could transform the lives of people living with the disease.
Europe will receive an extra 80 million doses of Moderna's mRNA-1273, a COVID-19 vaccine candidate, following the EC's decision.
